Source comparison
Does Sermorelin Help Perimenopause Research: Study Comparison
UC Pilot 2024 42 women, moderate-severe hot flashes 200 mcg 5×/week 12 weeks Hot flash frequency 31% reduction vs 9% placebo Statistically significant vasomotor improvement without altering hormone levels Brazilian DEXA 2023 36 perimenopausal women, BMI 27–32
This comparison does not assign a generated winner or score.
- UC Pilot 2024
- 42 women, moderate-severe hot flashes
- 200 mcg 5×/week
- 12 weeks
- Hot flash frequency
- 31% reduction vs 9% placebo
- Statistically significant vasomotor improvement without altering hormone levels
- Brazilian DEXA 2023
- 36 perimenopausal women, BMI 27–32
- 300 mcg 3×/week
- 16 weeks
- Visceral adipose tissue
- 4.2% VAT reduction vs 0.8% placebo
- Meaningful body composition shift, but effect requires continued training
- Sleep Quality 2022
- 28 women, PSQI >5
- 150 mcg nightly
- 8 weeks
- Pittsburgh Sleep Quality Index
- 3.1-point improvement vs 0.6 placebo
- Sleep architecture improved independent of hot flash reduction
- Bone Density 2021
- 50 postmenopausal women
- 24 weeks
- Lumbar spine BMD
- No significant change
- GH stimulation alone insufficient for bone preservation
- The comparison reveals a consistent pattern: sermorelin help perimenopause research demonstrates measurable effects on symptoms driven by autonomic or metabolic dysregulation. Vasomotor instability, sleep disruption, body composition. But shows limited impact on structural changes like bone density that require estrogen receptor activation.